Donate Help Contact The AHA Sign In Home
American Heart Association
Hypertension
Search: search_blue_button Advanced Search
Hypertension. 2003;42:548-554
Published online before print August 25, 2003, doi: 10.1161/01.HYP.0000090095.87899.36
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
42/4/548    most recent
01.HYP.0000090095.87899.36v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Pomposiello, S. I.
Right arrow Articles by McGiff, J. C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Pomposiello, S. I.
Right arrow Articles by McGiff, J. C.
Related Collections
Right arrow Hypertension - basic studies
Right arrow Ion channels/membrane transport

(Hypertension. 2003;42:548.)
© 2003 American Heart Association, Inc.


Scientific Contributions

5,6-Epoxyeicosatrienoic Acid Mediates the Enhanced Renal Vasodilation to Arachidonic Acid in the SHR

Silvia I. Pomposiello; John Quilley; Mairead A. Carroll; John R. Falck; John C. McGiff

From the Department of Pharmacology, New York Medical College (J.Q., M.A.C., J.C.M.), Valhalla; Pharmacia (S.I.P.), St Louis, Mo; and the Department of Biochemistry, University of Texas Southwestern Medical Center (J.R.F.), Dallas.

Correspondence to John C. McGiff, MD, Department of Pharmacology, New York Medical College, Valhalla, NY 10595. E-mail John_McGiff{at}nymc.edu

We have shown a cytochrome P450–dependent renal vasodilator effect of arachidonic acid in response to inhibition of cyclooxygenase and elevation of perfusion pressure, which was enhanced in the spontaneously hypertensive rat (SHR) and linked to increased production of and/or responsiveness to epoxyeicosatrienoic acids (EETs). In the SHR, vasodilation elicited by low doses of arachidonic acid was attenuated by the nitric oxide synthase inhibitor Nw-nitro-L-arginine (50 µmol/L), whereas the responses to high doses were unaffected. Inhibition of epoxygenases with miconazole (0.3 µmol/L) in the presence of Nw-nitro-L-arginine greatly reduced the renal vasodilator response to all doses of arachidonic acid. Tetraethylammonium (10 mmol/L), a nonselective K+ channel blocker, abolished the nitric oxide–independent renal vasodilator effect of arachidonic acid as well as the vasodilator effect of 5,6-EET, confirming that EET-dependent vasodilation involves activation of K+ channels. Under conditions of elevated perfusion pressure (200 mm Hg) and cyclooxygenase inhibition, 5,6-EET, 8, 9-EET, and 11,12-EET caused renal vasodilatation in both SHR and Wistar-Kyoto rats (WKY), whereas 14,15-EET produced vasoconstriction. 5,6-EET was the most potent renal vasodilator of the EET regioisomers in the SHR by a factor of 4 or more. In the SHR, 5,6-EET- and 11,12-EET–induced renal vasodilatation was >2-fold greater than that registered in WKY. Thus, the augmented vasodilator responses to arachidonic acid in the SHR is through activation of K+ channels, and 5,6-EET is the most likely mediator.


Key Words: kidney • rats, spontaneously hypertensive • cytochrome P450 • arachidonic acids • vasodilation




This article has been cited by other articles:


Home page
Am. J. Physiol. Renal Physiol.Home page
R. M. Nusing, H. Schweer, I. Fleming, D. C. Zeldin, and M. Wegmann
Epoxyeicosatrienoic acids affect electrolyte transport in renal tubular epithelial cells: dependence on cyclooxygenase and cell polarity
Am J Physiol Renal Physiol, July 1, 2007; 293(1): F288 - F298.
[Abstract] [Full Text] [PDF]


Home page
HypertensionHome page
I. Fleming and R. Busse
Endothelium-Derived Epoxyeicosatrienoic Acids and Vascular Function
Hypertension, April 1, 2006; 47(4): 629 - 633.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Renal Physiol.Home page
J. D. Imig
Epoxide hydrolase and epoxygenase metabolites as therapeutic targets for renal diseases
Am J Physiol Renal Physiol, September 1, 2005; 289(3): F496 - F503.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Regul. Integr. Comp. Physiol.Home page
N. W. Rajapakse, R. J. Roman, J. R. Falck, J. J. Oliver, and R. G. Evans
Modulation of V1-receptor-mediated renal vasoconstriction by epoxyeicosatrienoic acids
Am J Physiol Regulatory Integrative Comp Physiol, July 1, 2004; 287(1): R181 - R187.
[Abstract] [Full Text] [PDF]